Completed PHASE3 INTERVENTIONAL NCT00215436

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease

Sponsor: Dey

Conditions COPD

Interventions Formoterol Fumarate

Updated 6 times since 2017 Last updated: Nov 9, 2010 Started: Mar 31, 2005 Primary completion: Sep 30, 2005 Completion: Sep 30, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates COPD and is currently completed. Dey leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Data source: Dey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Buena Park, United States , Butte, United States , Camillus, United States , Charlotte, United States , Cherry Hill, United States , Cincinnati, United States , Clearwater, United States , Columbus, United States and 33 more locations